Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia

International Clinical Psychopharmacology

Volumn 15, Issue 1, 2000, Pages 29-34

  Tzanakaki, M ^a   Guazzelli, M ^b   Nimatoudis, I ^d   Zissis, N P ^c  

^a Psychiatric Hospital of Souda   (Greece)

^b UNIVERSITY OF PISA   (Italy)

^c Research Department   (Greece)

^d NONE

Author keywords

Fluoxetine; Major depression; Paroxetine; Remission

Indexed keywords

FLUOXETINE; VENLAFAXINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAY CARE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HEADACHE; HOSPITAL PATIENT; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MELANCHOLIA; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SWEATING; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0033958098     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015010-00004     Document Type: Article

References (28)

1. Arminen S-L, Ikonen U, Pulkkinen P, et al. (1994) A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients. Acta Psychiatr Scand 89:382-389.
2. Beasley CM, Holman SL, Potvin JH (1993) Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry 5:199-208.
3. Benkert O, Gründer G, Wetzel H, Hackett D (1996) A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 30:441-451.
4. Bothwell R, Scott J (1997) The influence of cognitive variables on recovery in depressed inpatients. J Affect Disord 43:207-212.
5. Clerc GE, Ruimy P, Verdeau-Pailles (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 9:139-143.
6. Costa e Silva JA (1998) Randomized, double-blind comparison of venlafaxine and fluoxetinc in outpatients with major depression. J Clin Psychiatry 59:352-357.
7. Dierick M, Ravizza L, Realini R, Martin A (1996) A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuro-Psychopharmacol Biol Psychiatr 20:57-71.
8. Faravelli C, Ambonetti A, Pallanti S, Pazzagli A (1986) Depressive relapses and incomplete recovery from an index episode. Am J Psychiatry 143:888-891.
9. Guelfi JD, White C, Hackett D, et al. (1995) Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry, 56:450-458.
10. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology, rev. edn. DHEW Pub. No. (ADM)76-338. Rockville, MD: National Institutes of Mental Health.
11. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
12. Judd LL, Akiskal HS, Maser JD, et al. (1998) Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50:97-108.
13. Kapur S, Mieczkowski T, Mann JJ (1992) Antidepressant medications and the relative risk of suicide attempts and suicide. JAMA 268:3441-3445.
14. Kessler RC, McGonagle KA, Zhao S, et al. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19.
15. Kiloh LG, Andrews G, Neilson M (1988) The long-term outcome of depressive illness. Br J Psychiatry 153:752-757.
16. Lecrubier Y, Bourin M, Moon CAL, et al. (1997) Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 95:485-493.
17. Lee AS, Murray RM (1988) The long-term outcome of Maudsley depressives. Br J Psychiatry 153:741-751.
18. Lepine J-P, on behalf of the DEPRES Steering Committee (1997) European perspective on depression. Prim Care Psychiatry 3 (Suppl 2):S3-S6.
19. Lin EHB, Katon WJ, VanKorff M, et al. (1998) Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med 7:443-449.
20. McPartlin GM, Reynolds A, Anderson C, Casoy J (1998) A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Psychiatry 4:127-132.
21. Mintz J, Mintz LI, Arruda MJ, Hwang SS (1992) Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 49:761-768.
22. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
23. Montgomery SA, Doogan DP, Burnside R (1991) The influence of different relapse criteria on the assessment of long-term efficacy of sertralinc. Int Clin Psychopharmacol 6 (Suppl 2):37-46.
24. Paykel ES, Ramana R, Cooper Z, et al. (1995) Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25:1171-1180.
25. Poirier M-F, Boyer P (1999) Double-blind, randomized comparison of venlafaxine and paroxetine for treatment-resistant depression. Br J Psychiatry, in press.
26. Tignol J, Stoker MJ, Dunbar GC (1992) Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 7:91-94.
27. Tylee A, Beaumont G, Bowden M, Reynolds A (1997) A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Prim Care Psychiatry 3:51-58.
28. Van Londen L, Molenaar RPG, Goekoop JG, et al. (1998) Three-to 5-year prospective follow-up of outcome of major depression. Psychol Med 28:731-735.